TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alibaba Health Information Technology ( (HK:0241) ) has shared an update.
Alibaba Health Information Technology Limited reported a significant financial performance for the year ending March 31, 2025, with a 13.2% increase in revenue and a 62.2% rise in net profit. The company achieved robust growth through its Tmall Healthcare Platform, driven by increased gross merchandise volume and active user engagement, alongside the integration of AI in its operations. The company is poised to benefit from favorable government policies aimed at boosting healthcare consumption and is actively participating in initiatives to lower consumption barriers through subsidies and discounts.
The most recent analyst rating on (HK:0241) stock is a Buy with a HK$5.50 price target. To see the full list of analyst forecasts on Alibaba Health Information Technology stock, see the HK:0241 Stock Forecast page.
More about Alibaba Health Information Technology
Alibaba Health Information Technology Limited operates within the ‘Internet + Healthcare’ industry, primarily focusing on pharmaceutical e-commerce and healthcare services. The company leverages technology to enhance its Tmall Healthcare Platform, offering a range of products and services, including healthcare advertising, and applying AI models to optimize its operations.
YTD Price Performance: 58.13%
Average Trading Volume: 147,544,593
Technical Sentiment Signal: Buy
Current Market Cap: HK$84.46B
For a thorough assessment of 0241 stock, go to TipRanks’ Stock Analysis page.